| 2.35 0.11 (4.91%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.79 | 1-year : | 4.69 |
| Resists | First : | 3.25 | Second : | 4.01 |
| Pivot price | 2.94  |
|||
| Supports | First : | 2 | Second : | 1.66 |
| MAs | MA(5) : | 2.26 |
MA(20) : | 3.08 |
| MA(100) : | 2.48 |
MA(250) : | 2.52 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 7.7 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 4.06 | Low : | 1.24 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BCAB ] has closed above bottom band by 26.2%. Bollinger Bands are 119.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.38 - 2.39 | 2.39 - 2.4 |
| Low: | 2.22 - 2.23 | 2.23 - 2.24 |
| Close: | 2.33 - 2.35 | 2.35 - 2.37 |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Fri, 19 Apr 2024
BioAtla, Inc.'s (NASDAQ:BCAB) recent 27% pullback adds to one-year year losses, institutional owners may take ... - Simply Wall St
Mon, 15 Apr 2024
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 9.0% in March - MarketBeat
Mon, 01 Apr 2024
Is Bioatla Inc (BCAB) a Leader in the Biotechnology Industry? - InvestorsObserver
Fri, 29 Mar 2024
BioAtla, Inc. (NASDAQ:BCAB) Forecasted to Earn FY2028 Earnings of ($0.09) Per Share - MarketBeat
Thu, 28 Mar 2024
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully - Yahoo Finance
Wed, 27 Mar 2024
BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 64.4 (%) |
| Shares Short | 5,590 (K) |
| Shares Short P.Month | 5,110 (K) |
| EPS | -2.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47 % |
| Return on Equity (ttm) | -98.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -104 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -0.92 |
| PEG Ratio | 0 |
| Price to Book value | 1.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|